BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3482 related articles for article (PubMed ID: 24634832)

  • 1. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF and brain structural imaging markers of the Alzheimer's pathological cascade.
    Yang X; Tan MZ; Qiu A
    PLoS One; 2012; 7(12):e47406. PubMed ID: 23284610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Commonly Measured Plasma and Cerebrospinal Fluid Proteins and Their Significance for the Characterization of Cognitive Impairment Status.
    Rehman H; Ang TFA; Tao Q; Espenilla AL; Au R; Farrer LA; Zhang X; Qiu WQ;
    J Alzheimers Dis; 2024; 97(2):621-633. PubMed ID: 38143358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.
    Benson GS; Bauer C; Hausner L; Couturier S; Lewczuk P; Peters O; Hüll M; Jahn H; Jessen F; Pantel J; Teipel SJ; Wagner M; Schuchhardt J; Wiltfang J; Kornhuber J; Frölich L
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):477-486. PubMed ID: 35061102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Efficient Combination among sMRI, CSF, Cognitive Score, and
    Khatri U; Kwon GR
    Comput Intell Neurosci; 2020; 2020():8015156. PubMed ID: 32565773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of Validated MicroRNA Biomarkers for Alzheimer's Disease in Mild Cognitive Impairment.
    Sandau US; Wiedrick JT; Smith SJ; McFarland TJ; Lusardi TA; Lind B; Harrington CA; Lapidus JA; Galasko DR; Quinn JF; Saugstad JA
    J Alzheimers Dis; 2020; 78(1):245-263. PubMed ID: 32955460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for ordering of Alzheimer disease biomarkers.
    Jack CR; Vemuri P; Wiste HJ; Weigand SD; Aisen PS; Trojanowski JQ; Shaw LM; Bernstein MA; Petersen RC; Weiner MW; Knopman DS;
    Arch Neurol; 2011 Dec; 68(12):1526-35. PubMed ID: 21825215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
    van Rossum IA; Vos SJ; Burns L; Knol DL; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; L'italien G; van der Flier WM; Teunissen CE; Blennow K; Barkhof F; Rueckert D; Wolz R; Verhey F; Visser PJ
    Neurology; 2012 Oct; 79(17):1809-16. PubMed ID: 23019259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
    Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
    Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
    Shaw LM; Vanderstichele H; Knapik-Czajka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter W; Lee VM; Trojanowski JQ;
    Ann Neurol; 2009 Apr; 65(4):403-13. PubMed ID: 19296504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid Alzheimer's Disease Biomarker Patterns of Change Prior to the Onset of Mild Cognitive Impairment.
    Sun Y; Moghekar A; Soldan A; Pettigrew C; Greenberg B; Albert M; Wang MC;
    J Alzheimers Dis; 2023; 96(1):287-300. PubMed ID: 37742656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 175.